Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4A | O75164 | 11/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131476 | 0.97 | ALDH1A1 (0.74) | ALDH1A1CHRNB2CHRNB4CHRNA4HTT | |
| SCHEMBL5948495 | 0.90 | ALDH1A1 (0.74) | ALDH1A1CHRNB2CHRNB4CHRNA4HTT | |
| SCHEMBL16945134 | 0.89 | ALDH1A1 (0.58) | ALDH1A1CHRNB2CHRNB4CHRNA4HTT | |
| SCHEMBL2484949 | 0.89 | ALDH1A1 (0.81) | ALDH1A1TSHR | |
| SCHEMBL13714936 | 0.89 | ALDH1A1 (0.81) | ALDH1A1TSHR | |
| SCHEMBL168532 | 0.89 | ALDH1A1 (0.81) | ALDH1A1TSHR | |
| SCHEMBL20993533 | 0.89 | TSHR (0.60) | ALDH1A1LMNAKDM4AKDM4CKDM5A | |
| SCHEMBL21703159 | 0.89 | TSHR (0.60) | ALDH1A1LMNAKDM4AKDM4CKDM5A | |
| SCHEMBL22406917 | 0.89 | ALDH1A1 (0.81) | ALDH1A1TSHR | |
| SCHEMBL9162783 | 0.89 | ALDH1A1 (0.58) | ALDH1A1CHRNB2CHRNB4CHRNA4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878975-B2 | Catalytic hydrogenation for producing amines from carboxylic acid amides, carboxylic acid diamides, di-, tri-, or polypeptides, or peptide amides | EVONIK DEGUSSA GMBH (DE) | 2018-01-30 | — | — | US | claimed |
| US-9878975-B2 | Catalytic hydrogenation for producing amines from carboxylic acid amides, carboxylic acid diamides, di-, tri-, or polypeptides, or peptide amides | EVONIK DEGUSSA GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-20160272571-A1 | Catalytic Hydrogenation for Producing Amines from Carboxylic Acid Amides, Carboxylic Acid Diamides, Di-, Tri-, or Polypeptides, or Peptide Amides | EVONIK DEGUSSA GMBH (DE) | 2016-09-22 | — | — | US | disclosed |
| US-7670631-B2 | Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. (PT) | 2010-03-02 | — | — | US | disclosed |
| EP-1601378-A2 | A METHOD FOR THE PREVENTION OF MALARIA INFECTION OF HUMANS BY HEPATOCYTE GROWTH FACTOR ANTAGONISTS | Instituto Gulbenkian de Ciencia (PT) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004080420-A2 | A METHOD FOR THE PREVENTION OF MALARIA INFECTION OF HUMANS BY HEPATOCYTE GROWTH FACTOR ANTAGONISTS | INSTITUTO GULBENKIAN DE CIENCIA (PT) | 2004-09-23 | — | — | WO | disclosed |
| US-20040185050-A1 | Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists | ALFAMA - INVESTIGACAO E DESENVOLVIMENTO DE PRODUTOS FARMACEUTICOS LDA. (PT) | 2004-09-23 | — | — | US | disclosed |
| EP-0594577-B1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHOD OF USE THEREOF | SLOAN KETTERING INST CANCER (US) | 1998-12-30 | — | — | EP | disclosed |
| US-5840960-A | ANTITUMOR | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1998-11-24 | — | — | US | disclosed |
| US-5608108-A | ANTITUMOR AGENTS; LUNG, BLADDER, KIDNEY, BREAST, COLORECTAL | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0594577-A1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHOD OF USE THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 1994-05-04 | — | — | EP | disclosed |
| US-5175191-A | Antitumor agents or anticancer agents | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-12-29 | — | — | US | disclosed |
| US-5055608-A | Antitumor, anticarcinogenic agents | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1991-10-08 | — | — | US | disclosed |
| WO-1991008191-A1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHOD OF USE THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1991-06-13 | — | — | WO | disclosed |
| WO-1991000257-A1 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1991-01-10 | — | — | WO | disclosed |
| WO-1990009092-A2 | NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHOD OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1990-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272571-A1 | Catalytic Hydrogenation for Producing Amines from Carboxylic Acid Amides, Carboxylic Acid Diamides, Di-, Tri-, or Polypeptides, or Peptide Amides | DAO, DDC, HDGF | ALDH1A1 2121/4885CHRNB2 4090/4885CHRNB4 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.